JP2017523239A5 - - Google Patents

Download PDF

Info

Publication number
JP2017523239A5
JP2017523239A5 JP2017525514A JP2017525514A JP2017523239A5 JP 2017523239 A5 JP2017523239 A5 JP 2017523239A5 JP 2017525514 A JP2017525514 A JP 2017525514A JP 2017525514 A JP2017525514 A JP 2017525514A JP 2017523239 A5 JP2017523239 A5 JP 2017523239A5
Authority
JP
Japan
Prior art keywords
seq
nucleic acid
protein
rpgr
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017525514A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523239A (ja
JP6654760B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/040866 external-priority patent/WO2016014353A1/en
Publication of JP2017523239A publication Critical patent/JP2017523239A/ja
Publication of JP2017523239A5 publication Critical patent/JP2017523239A5/ja
Priority to JP2019235539A priority Critical patent/JP6966532B2/ja
Application granted granted Critical
Publication of JP6654760B2 publication Critical patent/JP6654760B2/ja
Priority to JP2021172128A priority patent/JP7198329B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017525514A 2014-07-24 2015-07-17 網膜色素変性症のためのrpgr遺伝子治療 Active JP6654760B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2019235539A JP6966532B2 (ja) 2014-07-24 2019-12-26 網膜色素変性症のためのrpgr遺伝子治療
JP2021172128A JP7198329B2 (ja) 2014-07-24 2021-10-21 網膜色素変性症のためのrpgr遺伝子治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462028638P 2014-07-24 2014-07-24
US62/028,638 2014-07-24
PCT/US2015/040866 WO2016014353A1 (en) 2014-07-24 2015-07-17 Rpgr gene therapy for retinitis pigmentosa

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019235539A Division JP6966532B2 (ja) 2014-07-24 2019-12-26 網膜色素変性症のためのrpgr遺伝子治療

Publications (3)

Publication Number Publication Date
JP2017523239A JP2017523239A (ja) 2017-08-17
JP2017523239A5 true JP2017523239A5 (cg-RX-API-DMAC7.html) 2018-08-16
JP6654760B2 JP6654760B2 (ja) 2020-02-26

Family

ID=55163577

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017525514A Active JP6654760B2 (ja) 2014-07-24 2015-07-17 網膜色素変性症のためのrpgr遺伝子治療
JP2019235539A Active JP6966532B2 (ja) 2014-07-24 2019-12-26 網膜色素変性症のためのrpgr遺伝子治療
JP2021172128A Active JP7198329B2 (ja) 2014-07-24 2021-10-21 網膜色素変性症のためのrpgr遺伝子治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019235539A Active JP6966532B2 (ja) 2014-07-24 2019-12-26 網膜色素変性症のためのrpgr遺伝子治療
JP2021172128A Active JP7198329B2 (ja) 2014-07-24 2021-10-21 網膜色素変性症のためのrpgr遺伝子治療

Country Status (18)

Country Link
US (2) US10314924B2 (cg-RX-API-DMAC7.html)
EP (2) EP3191139B1 (cg-RX-API-DMAC7.html)
JP (3) JP6654760B2 (cg-RX-API-DMAC7.html)
CN (1) CN107206105A (cg-RX-API-DMAC7.html)
CA (1) CA2991750C (cg-RX-API-DMAC7.html)
CY (1) CY1123793T1 (cg-RX-API-DMAC7.html)
DK (2) DK3191139T3 (cg-RX-API-DMAC7.html)
ES (2) ES2987090T3 (cg-RX-API-DMAC7.html)
FI (1) FI3821912T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20241154T1 (cg-RX-API-DMAC7.html)
HU (2) HUE052781T2 (cg-RX-API-DMAC7.html)
LT (2) LT3191139T (cg-RX-API-DMAC7.html)
PL (2) PL3821912T3 (cg-RX-API-DMAC7.html)
PT (2) PT3821912T (cg-RX-API-DMAC7.html)
RS (2) RS61307B1 (cg-RX-API-DMAC7.html)
SI (2) SI3191139T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202400309T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016014353A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE052781T2 (hu) * 2014-07-24 2021-05-28 Massachusetts Eye & Ear Infirmary RPGR génterápia a retinitis pigmentosa terápiájára
WO2016098078A2 (en) * 2014-12-19 2016-06-23 Novartis Ag Dimerization switches and uses thereof
EP3268481B1 (en) * 2015-03-11 2020-05-27 The United States of America, as represented by The Secretary, Department of Health and Human Services Rpgr vectors for treating x-linked retinitis pigmentosa
GB201516066D0 (en) 2015-09-10 2015-10-28 Young & Co Llp D Treatment of retinitis pigmentosa
GB201704192D0 (en) 2017-03-16 2017-05-03 Nightstarx Ltd Treatment of Retinitis Pigmentosa
KR102763312B1 (ko) * 2017-10-20 2025-02-07 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 치료적으로 유효한 양의 재조합 aav9- 유도 벡터의 망막하 전달을 포함하는 대상체의 원추 광수용체 내 관심의 폴리뉴클레오티드를 발현하는 방법
DK3710590T3 (da) * 2017-11-15 2024-08-12 Univ Michigan Regents Virale vektorer omfattende rdh12-kodende områder og fremgangsmåder til behandling af nethindedystrofier
WO2021183779A1 (en) 2020-03-11 2021-09-16 Massachusetts Eye And Ear Infirmary Gene therapy for nmnat1-associated retinal degeneration
CN120350069A (zh) * 2024-01-12 2025-07-22 北京中因科技有限公司 视网膜色素变性动物模型及其构建方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
ATE68013T1 (de) 1985-07-05 1991-10-15 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
WO1989002468A1 (en) 1987-09-11 1989-03-23 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
WO1989005345A1 (en) 1987-12-11 1989-06-15 Whitehead Institute For Biomedical Research Genetic modification of endothelial cells
ATE152169T1 (de) 1988-02-05 1997-05-15 Whitehead Biomedical Inst Modifizierte hepatozyten und deren anwendung
AU656544B2 (en) 1990-10-31 1995-02-09 Brigham And Women's Hospital Genetic modification of endothelial cells
US5767079A (en) * 1992-07-08 1998-06-16 Celtrix Pharmaceuticals, Inc. Method of treating ophthalmic disorders using TGF -β
WO2001038578A1 (en) * 1999-11-24 2001-05-31 Cornell Research Foundation, Inc. Inherited retinal diseases at the canine rp3 locus: linkage, marker- and mutation-based tests
GB0008801D0 (en) * 2000-04-10 2000-05-31 Medical Res Council Sequences
CN102925445A (zh) * 2011-08-08 2013-02-13 刘军 一种获得rpgr 基因新的转录剪切形式的方法
EP2872183B1 (en) * 2012-07-11 2018-09-26 The Trustees Of The University Of Pennsylvania Aav-mediated gene therapy for rpgr x-linked retinal degeneration
GB201412011D0 (en) * 2014-07-04 2014-08-20 Ucl Business Plc Treatments
HUE052781T2 (hu) * 2014-07-24 2021-05-28 Massachusetts Eye & Ear Infirmary RPGR génterápia a retinitis pigmentosa terápiájára

Similar Documents

Publication Publication Date Title
JP2017523239A5 (cg-RX-API-DMAC7.html)
JP2020073536A5 (cg-RX-API-DMAC7.html)
US12180500B2 (en) Chimeric capsids
AU2013287281B2 (en) AAV-mediated gene therapy for RPGR x-linked retinal degeneration
HRP20202023T1 (hr) Genska terapija rpgr za liječenje retinitis pigmentose
JP2015508760A5 (cg-RX-API-DMAC7.html)
JP2015523379A5 (cg-RX-API-DMAC7.html)
Manfredi et al. Combined rod and cone transduction by adeno-associated virus 2/8
JP2017510296A5 (cg-RX-API-DMAC7.html)
JP2018520646A5 (cg-RX-API-DMAC7.html)
JP2014518614A (ja) 変異体キャプシドを有するアデノ関連ウイルスビリオンおよびその使用方法
KR20210028162A (ko) 지대근 이영양증 2a형을 치료하기 위한 재조합 아데노 연관 바이러스 생성물 및 방법
JP2019537437A5 (cg-RX-API-DMAC7.html)
JP2016535034A5 (cg-RX-API-DMAC7.html)
CN104936606A (zh) 糖原贮积病的基因疗法
JP2021502978A5 (cg-RX-API-DMAC7.html)
IL308645A (en) Viral vectors comprising rdh12 coding regions and methods of treating retinal dystrophies
BR112021012048A2 (pt) Fator complementar i e cofator de fator complementar i, vetores que codificam os mesmos e uso terapêutico
JP2019524090A5 (cg-RX-API-DMAC7.html)
RU2019126509A (ru) Выделенный модифицированный белок VP1 капсида аденоассоциированного вируса 5 серотипа (AAV5), капсид и вектор на его основе
EP3707262A1 (en) Compositions and methods for inhibiting viral vector-induced inflammatory responses
JP2018526994A5 (cg-RX-API-DMAC7.html)
JP2018509154A5 (cg-RX-API-DMAC7.html)
JP2021520232A (ja) 黄斑ジストロフィーを処置するための組成物及び方法
HK1253299A1 (zh) 一种通过基因治疗治疗眼疾病的改进方法